China Next-Generation Sequencing Market worth $2.84 billion by 2031
The report "China Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031", is expected to reach USD 2.84 billion by 2031 from USD 1.35 billion in 2026, at a CAGR of 16.0% from 2026 to 2031.
Browse 200 market data Tables and 40 Figures spread through 300 Pages and in-depth TOC on "China Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Platforms, Bioinformatics), Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/china-next-generation-sequencing-market-77992161.html
Key drivers of growth in the China next-generation sequencing market include advancements in sequencing platforms that have become more efficient and cost-effective, increased demand for precision medicine, and declining sequencing technology costs. Rising clinical applications in diagnostics and oncology are driving market expansion, particularly as the aging population and the increasing incidence of chronic diseases drive healthcare needs. The expansion of major players into the Chinese market and favorable regulatory reforms are supporting the adoption of next-generation sequencing solutions. Urban areas with stronger technological infrastructure are particularly well-positioned to support genomic studies and advanced sequencing applications. The integration of artificial intelligence and machine learning with next-generation sequencing is also creating opportunities for enhanced data management and analytics.
The sequencing services segment is expected to register significant growth during the forecast period.
Sequencing services are expanding within the China next-generation sequencing market, given their essential role in genomic research. China exhibits substantial opportunities in this segment as demand continues to grow in academic research and healthcare applications. Sequencing services support personalized medicine initiatives and genomics research, enabling researchers and clinicians to access advanced sequencing capabilities without requiring significant capital investment in platforms and infrastructure. The services segment provides flexibility for institutions to scale their sequencing needs according to project requirements while benefiting from specialized expertise in sample preparation, sequencing operations, and quality control.
The clinical diagnostics application segment is projected to account for a significant share of the China next-generation sequencing market.
Clinical diagnostics represents a major application area for next-generation sequencing technologies. The widespread application of next-generation sequencing in clinical diagnostics continues to grow as the incidence of chronic diseases rises. Clinical applications include genetic testing, disease diagnosis, treatment selection, and monitoring of therapeutic responses. Next-generation sequencing enables comprehensive genomic profiling that supports precision medicine approaches, allowing healthcare providers to tailor treatments based on individual patient genetic profiles. The technology is particularly valuable in oncology applications where genomic information guides cancer diagnosis and treatment decisions. As healthcare systems increasingly adopt genomic medicine, clinical diagnostics applications are expected to contribute substantially to market growth.
China is expected to be a dominant force in the Asia Pacific next-generation sequencing market during the forecast period.
China is positioned as a significant contributor to the Asia Pacific next-generation sequencing market. The country benefits from substantial growth in pharmaceutical research and favorable regulatory reforms that support the adoption of advanced sequencing technologies. Rapid urbanization and population growth in China are creating a larger healthcare service base and increasing demand for diagnostic solutions. The expansion of research infrastructure and investment in genomics research are strengthening China's position in the regional market. Government initiatives to develop precision medicine and biotechnology are creating a favorable environment for the adoption of next-generation sequencing. The presence of domestic companies alongside international players is fostering competitive dynamics that drive innovation and market development during the forecast period.
The report profiles key players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), BGI Group (China), MGI Tech (China), Berry Genomics (China), and Novogene Co., Ltd. (China), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the China Next-Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
